(84 days)
No
The device is a liquid control solution for verifying the performance of blood glucose meters. There is no mention of any software, algorithms, or data processing that would suggest the use of AI or ML.
No.
Explanation: The device is a control solution used to verify the performance of blood glucose monitoring systems, not to treat or diagnose a disease.
No.
Explanation: The device is a control solution used to verify the performance of blood glucose monitoring systems, not to diagnose a condition in a patient.
No
The device description clearly states it is a liquid glucose control solution packaged in plastic bottles, indicating it is a physical product, not software.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Explicit Statement: The "Intended Use / Indications for Use" section clearly states: "For In Vitro Diagnostic Use".
- Purpose: The device is a control solution used to verify the performance of blood glucose monitoring (BGM) systems. This verification process is performed in vitro (outside the body) on test strips that are used to measure glucose in a biological sample (blood).
- Regulatory Context: Control solutions for diagnostic devices like blood glucose meters are typically classified as IVDs by regulatory bodies because they are essential for ensuring the accuracy and reliability of the diagnostic test.
N/A
Intended Use / Indications for Use
LifeScan OneTouch Ultra control solution is intended to be used to monitor and evaluate the analytical performance of LifeScan BGM family systems using the OneTouch Ultra or OneTouch FastTake test strips.
LifeScan OneTouch Ultra control solution is intended for use to verify the performance of LifeScan BGM systems using the OneTouch Ultra or OneTouch FastTake test strips at glucose levels within the reportable range. The Glucose Control Solution is intended for use by healthcare professionals and people with diabetes mellitus at home.
For In Vitro Diagnostic Use
Product codes (comma separated list FDA assigned to the subject device)
JJX
Device Description
LifeScan OneTouch Ultra control solution is a single-level, viscosity-adjusted, aqueous liquid glucose control solution. LifeScan OneTouch Ultra control solution provides a convenient method of performing periodic QC checks for laboratories selecting to measure liquid QC material as a part of their quality assurance program. The product is packaged in plastic bottles with dropper tips for application of the solution to test strips. The control has a red color to help users see the solution while dispensing onto a test strip.
LifeScan OneTouch Ultra control solution contains glucose representing typical, normal-range glucose values in blood to verify performance of LifeScan BGM systems using the OneTouch Ultra or OneTouch FastTake test strips.
LifeScan OneTouch Ultra control solution is a non-hazardous aqueous solution containing no biological materials.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
healthcare professionals and people with diabetes mellitus at home.
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Tests were conducted to verify specific performance requirements:
- a) Closed bottle stability
- b) Stability after opening
- c) Test precision and range
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 862.1660 Quality control material (assayed and unassayed).
(a)
Identification. A quality control material (assayed and unassayed) for clinical chemistry is a device intended for medical purposes for use in a test system to estimate test precision and to detect systematic analytical deviations that may arise from reagent or analytical instrument variation. A quality control material (assayed and unassayed) may be used for proficiency testing in interlaboratory surveys. This generic type of device includes controls (assayed and unassayed) for blood gases, electrolytes, enzymes, multianalytes (all kinds), single (specified) analytes, or urinalysis controls.(b)
Classification. Class I (general controls). Except when intended for use in donor screening tests, quality control materials (assayed and unassayed) are exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.
0
KC022769
BIONOSTI
NOV 13 2002
510(k) Summary1
- (a) (1) Submitter's name, address Bionostics, Inc. 7 Jackson Road Devens, MA 01432
Contact Person Kathleen Storro Director, QA & Regulatory Affairs (978) 772-7070 x 220
Date of preparation of this summary: 15 August 2002
- (2) Device trade or proprietary name: LifeScan OneTouch Ultra control solution
Device common or usual name or classification name:
Single Analyte Control, All Types (Assayed and Unassayed)
| CLASSIFICATION | |||
|---|---|---|---|
| PRODUCT NOMENCLATURE | NUMBER | CLASS | PANEL |
| SINGLE ANALYTE CONTROL SOLUTION | 862.1660 75 JJX | I | CHEMISTRY |
(3) Substantial Equivalence
There has been no change in formulation, labeling or intended use of the control solution since the original 510(k) submission, K000318. The purpose of this 510(k) submission is to extend the use of this control to all LifeScan family of meters using the OneTouch Ultra or OneTouch FastTake glucose test strips, namely:
OneTouch FastTake Blood Glucose Meter, K011479 InDuo Blood Glucose Meter, K011616 UltraSmart Blood Glucose Meter, K021819
(4) Description of the new device
LifeScan OneTouch Ultra control solution is a single-level, viscosity-adjusted, aqueous liquid glucose control solution. LifeScan OneTouch Ultra control solution provides a convenient method of performing periodic QC checks for laboratories selecting to measure liquid QC material as a part of their quality assurance program. The product is packaged in plastic bottles with dropper tips for application of the solution to test strips. The control has a red color to help users see the solution while dispensing onto a test strip.
LifeScan OneTouch Ultra control solution contains glucose representing typical, normal-range glucose values in blood to verify performance of LifeScan BGM systems using the OneTouch Ultra or OneTouch FastTake test strips.
4 This summary of safety and effectiveness is submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.
1
LifeScan OneTouch Ultra control solution is a non-hazardous aqueous solution containing no biological materials.
(5) Intended use of the device
LifeScan OneTouch Ultra control solution is intended to be used to monitor and evaluate the analytical performance of LifeScan BGM family systems using the OneTouch Ultra or OneTouch FastTake test strips.
(6) Technological characteristics of the device.
This material consists of viscosity-adjusted, aqueous glucose control solution prepared in to represent normal, whole blood glucose values. The solution has been optimized to simulate the response of whole blood on LifeScan BGM family systems using the OneTouch Ultra or OneTouch FastTake test strips.
(b) (1) Summary of non-clinical tests submitted with the premarket notification for the device.
Tests were conducted to verify specific performance requirements:
- a) Closed bottle stability
- b) Stability after opening
- c) Test precision and range
Summary of clinical tests submitted with the premarket notification for the (b) (2) device.
N/A
(b) (3) Conclusions drawn from the clinical and non-clinical trials.
Comparison of technological characteristics, formulation and intended use to predicate devices listed in this summary support the claim of substantial equivalence.
2
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/2/Picture/1 description: The image is a black and white logo for the U.S. Department of Health & Human Services. The logo features a stylized eagle with three wavy lines representing its body and wings. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" are arranged in a circular pattern around the eagle.
NOV 1 3 2002
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
Ms. Kathleen Storro Director, QA and Regulatory Affairs Bionostics, Inc. 7 Jackson Road Devens, MA 01432
Re: K022769
Trade/Device Name: LifeScan OneTouch Ultra Control Solution Regulation Number: 21 CFR 862.1660 Regulation Name: Quality Control Material (Assayed and Unassayed) Regulatory Class: Class I Product Code: JJX Dated: August 19, 2002 Received: August 21, 2002
Dear Ms. Storro:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
3
. Page 2 -
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".
Sincerely yours,
Steven Butman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
4
510(k) Number
LifeScan OneTouch Ultra control solution Device Name:
Indications for Use:
LifeScan OneTouch Ultra control solution is intended for use to verify the performance of LifeScan BGM systems using the OneTouch Ultra or OneTouch FastTake test strips at glucose levels within the reportable range. The Glucose Control Solution is intended for use by healthcare professionals and people with diabetes mellitus at home.
For In Vitro Diagnostic Use
ttan Cooper
Division Sign-Off) Division of Clinical Laboratory D 510(k) Number .
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use (Per 21 CFR 801.109) OR
Over-The-Counter Use
(Optional Format 1-2-96)
OneTouch Ultra 510(k)